Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results


1.		Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				PANC0002 95533, CPTK787AUS08, NCT00185588, PANC0002, NCT00185588


2.		PTK/ZK in Disseminated Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				UKSH A-105 EudraCT No. 2005-002192-32, NCT00615160

Last Modified: 1/12/2009 First Published: 10/25/2003


3.		Phase II Study of Vatalanib in Patients With Primary or Secondary Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				CALGB-10105 NCT00072475


4.		PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				05-0639 IND#: 72,721, NCT00240162

Last Modified: 5/10/2007 First Published: 6/23/2006


5.		Phase II Study of Vatalanib in Patients With Recurrent or Progressive Meningioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				NU-05C4 NU-1398-025, NOVARTIS-NU-05C4, NCT00348790


6.		Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				PTK787/ZK222584 LSU IRB-6355, NCT00590343


7.		The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CPTK787/ZK222584 NCT00627198

Last Modified: 5/12/2007 First Published: 10/14/2006


8.		Phase I Study of Vatalanib and Pemetrexed Disodium in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MAYO-MC0515 MAYO-06-002065, NOVARTIS-CPTK787AUS16, NCT00390000


9.		PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				06-013 NCT00385853

Last Modified: 6/23/2008 First Published: 4/8/2008


10.		Phase I Study of Everolimus and Vatalanib in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MAYO-MC0414 MC0414, NCT00655655

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute